Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D. pt.) in children
| Autor: | M. Sähn, Th. Hirsch, Wolfgang Leupold |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Male
medicine.medical_specialty Allergy Nasal Provocation Tests Rhinitis Allergic Perennial Adolescent Immunology Placebo-controlled study Administration Oral Placebo Gastroenterology Bronchial Provocation Tests Double-Blind Method Oral administration Internal medicine medicine Humans Immunology and Allergy Antigens Dermatophagoides Child Glycoproteins Skin Tests Asthma House dust mite biology Cumulative dose business.industry Immunoglobulin E medicine.disease biology.organism_classification Surgery Immunoglobulin G Concomitant Pediatrics Perinatology and Child Health Female Immunotherapy Bronchial Hyperreactivity business |
| Zdroj: | Pediatric Allergy and Immunology. 8:21-27 |
| ISSN: | 1399-3038 0905-6157 |
| DOI: | 10.1111/j.1399-3038.1997.tb00138.x |
| Popis: | Safety and efficacy of sublingual (sublingual-swallow) immunotherapy (IT) with house dust mite extract were evaluated in 30 children (6 - 152/3 years of age) over the first 12 months of an ongoing study. The cumulative dose was 570 μg Der p I (five times that administered with subcutaneous therapy). Safety: One patient on active treatment dropped out after 8 weeks because of a subjective feeling of severe weakness, questionably induced by the therapy. Five patients on active therapy and one patient on placebo reported minor local side effects. Efficacy: Pulmonary symptoms were reduced after 12 months in actively treated asthmatics, but this was not consistent with the lack of improvement in bronchial reactivity, skin sensitivity and specific IgG and IgG4 against D. pt. in this group. In patients with rhinitis nasal sensitivity was reduced in the placebo group without concomitant improvement in the nasal symptom score. Specific IgE (D. pt. and D. f.) in creased significantly more in the active treatment group after 3 and 12 months. We conclude that sublingual IT over 12 months with the fivefold Der p 1 dose of subcutaneous IT was well tolerated, but there was no consistent clinical or immunological benefit compared to placebo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text